氯法齐明治疗结核病的临床应用指南  

Guideline for clinical application of clofazimine in the treatment of tuberculosis

作　　者：无 初乃惠[1] 陈效友[1] 周文强[1] 荆玮[1] 聂文娟[1] 戈启萍[1] 无;CHU Nai-hui;CHEN Xiao-you(Beijing Chest Hospital,Capital Medical University;Clinical Trial Branch of the Chinese Antituberculosis Association;Editorial Board of Chinese Journal of Antituberculosis)

机构地区：[1]首都医科大学附属北京胸科医院,101149 [2]中国防痨协会临床试验专业分会 [3]《中国防痨杂志》编辑委员会

出　　处：《中国防痨杂志》2020年第5期409-417,共9页Chinese Journal of Antituberculosis

基　　金：“十三五”国家科技重大专项(2017ZX09304009);“十二五”国家科技重大专项(2015ZX10003001-002)。

摘　　要：氯法齐明作为治疗耐药结核病的核心药物之一,由于缺乏规范性指导意见,中国防痨协会临床试验专业分会与《中国防痨杂志》编辑委员会组织相关专家制定本指南。本指南介绍了氯法齐明的分子结构与作用机制、药效学与药代动力学、耐药机制、不同类型人群的临床应用、适应证与禁忌证、剂量用法、化疗方案的制订,以及不良反应和临床应用注意事项等内容,以期对临床规范使用氯法齐明起到指导性作用。Clofazimine,as one of the core drugs for the treatment of drug-resistant tuberculosis,lacks regulatory guideline.The Clinical Trial Branch of the Chinese Antituberculosis Association and the Editorial Board of Chinese Journal of Antituberculosis organized relevant experts to develop this guideline.This guideline formulated the molecular structure,mechanism of action,pharmacodynamics and pharmacokinetics,mechanism of drug resistance,indications and contraindications,dosage,chemotherapy regimen,adverse effect and precautions for clinical application to guide the clinical application for different population with clofazimine in practice.

关 键 词：结核 结核 抗多种药物性 氯法齐明 治疗应用 实践指南 

分 类 号：R52[医药卫生—内科学]